^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Erbitux (cetuximab)

    i
    Other names: C 225, IMC-C225, LY2939777, C225-03, ch225, C225, IMC C225, LY-2939777, IMCC225, LY 2939777, C-225
    Company:
    BMS, EMD Serono, Eli Lilly
    Drug class:
    EGFR inhibitor
    Related drugs:
    1d
    A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101) (clinicaltrials.gov)
    P1, N=590, Recruiting, GlaxoSmithKline | N=316 --> 590
    Enrollment change • Pan tumor
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • risvutatug rezetecan (GSK5764227)
    1d
    Switch from cetuximab to panitumumab during encorafenib-based therapy in BRAF V600E mutated metastatic colorectal cancer: an international multicenter analysis from the AGEO group. (PubMed, Clin Res Hepatol Gastroenterol)
    No new IRRs nor toxic deaths were reported. ENCO-PANI appears to be as safe and effective in pts treated for a BRAFm mCRC unable to continue CET and may represent a valid alternative therapeutic option in this setting.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • MSI-H/dMMR • BRAF V600
    |
    Erbitux (cetuximab) • Vectibix (panitumumab) • Braftovi (encorafenib)
    1d
    Oncolytic HSV-1-Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis. (PubMed, Cancer Res)
    Clinically, the Notch ligand JAG1 was upregulated in recurrent high-grade glioma patients treated with the oHSV CAN-3110 and correlated with poor prognosis. Heightened EGFR activation in senescent cells was a mechanism to escape cell death, which created a unique opportunity for cetuximab as a senolytic agent. Combination therapy reduced EGFR signaling and induced macrophage-mediated antibody-dependent cellular cytotoxicity, thereby increasing the anti-tumor therapeutic efficacy of OD-0J1.
    Journal
    |
    HMGB1 (High Mobility Group Box 1) • CDK1 (Cyclin-dependent kinase 1) • IL1B (Interleukin 1, beta) • JAG1 (Jagged Canonical Notch Ligand 1)
    |
    Erbitux (cetuximab) • linoserpaturev (CAN-3110)
    1d
    A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors (clinicaltrials.gov)
    P1, N=437, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Opdivo (nivolumab) • Erbitux (cetuximab) • Krazati (adagrasib)
    1d
    Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=44, Completed, Bristol-Myers Squibb | Terminated --> Completed
    Trial completion
    |
    Opdivo (nivolumab) • Erbitux (cetuximab)
    2d
    Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=128, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Erbitux (cetuximab) • cisplatin • carboplatin • paclitaxel • docetaxel • fluorouracil topical
    2d
    CEIL: Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=198, Recruiting, Sun Yat-sen University | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
    |
    BRAF wild-type
    |
    Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Enweida (envafolimab)
    2d
    A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies (clinicaltrials.gov)
    P1/2, N=252, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • gemcitabine • albumin-bound paclitaxel
    3d
    A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) (clinicaltrials.gov)
    P1/2, N=190, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • patritumab deruxtecan (U3-1402) • Jiataile (sacituzumab tirumotecan) • calderasib (MK-1084)
    4d
    A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation (clinicaltrials.gov)
    P1/2, N=440, Recruiting, Tyligand Pharmaceuticals (Suzhou) Limited | N=150 --> 440
    Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Erbitux (cetuximab) • paclitaxel • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium
    4d
    Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System (clinicaltrials.gov)
    P2, N=86, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    |
    Erbitux (cetuximab) • Rybrevant (amivantamab-vmjw)
    4d
    HAMMER: A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) (clinicaltrials.gov)
    P1/2, N=175, Terminated, Synthorx, Inc, a Sanofi company | N=250 --> 175 | Active, not recruiting --> Terminated; The study was terminated as per Sponsor decision. The decision was not related to any safety concerns.
    Enrollment change • Trial termination
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • pegenzileukin (SAR444245)